Cyclerion Therapeutics (CYCN) Reports on CY6463 Clinical Pipeline Progress streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
- Highlights included positive Phase 2b data with COMP360 from a ground-breaking treatment resistant depression (TRD) trial, highly encouraging Phase 2a proof-of-mechanism data with RL-007 in cognitive
/PRNewswire/ Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2021. "Our third.
Neurocrine Biosciences Reports First Quarter 2021 Financial Results
INGREZZA® (valbenazine) First Quarter 2021 Net Product Sales of $230 Million with Approximately 43,300 TRx
Initiated Pediatric Phase III Registrational Program of Crinecerfont for the Treatment of Classic Congenital Adrenal Hyperplasia
Initiated Phase II Study of NBI-827104 in Essential Tremor
News provided by
Share this article
Share this article
SAN DIEGO, May 5, 2021 /PRNewswire/ Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2021 and provided revised full-year 2021 financial expense guidance. Our first quarter results reflect a lower than normal refill rate per patient due to the typical seasonal payor dynamics for INGREZZA that were exacerbated by COVID. Importantly, we did not see an increase in discontinuations and exited the quarter with more patients on INGREZZA versus the prior quarter. New patient starts did pick up late